Biogen stock surges 37% after receiving FDA approval for Alzheimer’s drug
Longterm shareholders of Biogen (NASDAQ:BIIB) rejoice today after the company received accelerated approval from the FDA for their Alzheimer’s treatment ADUHELM™. The approval marks a historic day as ADUHELM becomes the first treatment to receive approval that addresses an underlying pathology of the disease. Looking ahead, Biogen will “conduct a controlled trial to verify the …
Biogen stock surges 37% after receiving FDA approval for Alzheimer’s drug Read More »